BioSpace News Archive

Relatively higher risks of complications associated with cardiac surgical activities gain ground in the adoption of aortic cannula systems.

The cell therapy technologies market is expected to gain immense growth opportunities through the forecast period of 2019-2029 owing to the rising influence of cell therapies across the life sciences sector.

The global analytical standards market provides increasing public concerns related to optimum food quality and safety, increasing applications of different analytical techniques in proteomics & metabolomics, and better regulatory emphasis on efficient pollution control and monitoring are some of the important factors driving the growth of the analytical standards market.

PsiOxus Therapeutics, Ltd. announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® to treat a range of tumor types in late-stage cancer patients.

Patent supports the unique potential of Biofidelity’s technology to deliver ultra-sensitive detection of guideline-recommended tumor markers

WebMD PracticePro provides medical practices the most comprehensive set of growth tools available to engage patients at every step of the patient journey

Dr. Reddy’s Laboratories Ltd. announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan® Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration.

NorthStar Anesthesia, an industry leader in providing modernized anesthesia care for over two decades, has expanded to serve new states and regional systems across the country.

Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases, announced that management will be presenting at the 19th Annual Virtual Needham Healthcare Conference on Wednesday, April 14 at 11:40 a.m. ET.